Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2025 Earnings Presentation
13 slides from Indivior Pharmaceuticals's earnings presentation, Apr 24, 2025
Slide 1: Q1 2025 Results
Q1 2025 Results April 24, 2025 Exhibit 99.2
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Q1 2025 Results | april 24, 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company’s financial guida
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q1 2025 Overview
Q1 2025 Results | April 24, 2025 Q1 2025 Overview1 %-comparisons versus revised Q1 2024 See Non-GAAP Financial Measures in the Appendix for reconciliation NM = Not Meaningful; OHS = Organized Health Systems Overall results in line with planning assumptions and FY 2025 outlook SUBLOCADE NR as expecte
Slide 5: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 6: Q1 2025 Financial Highlights
$ mil Q1 2025 Q1 2024 Change Net Revenue (NR): U.S. NR ROW2 NR $266 222 44 $284 241 42 (6)% (8)% 3% Gross Profit: Gross Margin $221 83% $246 87% (10)% (400) Bps Operating Expenses: SG&A R&D Litigation Settlement ($155) (132) (22) (1) ($171) (143) (28) - (9)% (8)% (19)% NM Operating Expenses – Non-GA
Slide 7: Cash and Borrowing Position
Q1 2025 Results | April 24, 2025 Cash and Borrowing Position Cash and Borrowings: KEY TAKEAWAYS: (vs. December 31, 2024, unless otherwise indicated) 1. See discussion of obligations in Note 12 in SEC filed form 10-K on March 3, 2025 Cash & Investments of $400m1 Cash generated by operations and reduc
Slide 8: FY 2025 Guidance
Q1 2025 Results | April 24, 2025 FY 2025 Guidance1 TOP-LINE ASSUMPTIONS: Gross MARGIN & EXPENSE CONSIDERATIONS: As of April 24, 2025, before exceptional items and assuming no material change in key FX rates vs. FY 2024 average rates Assumes no material change to Medicaid eligibility policy and/or ot
Slide 9: Q&A
Nz AS INDIVIOR’ Q&A
Slide 10: Appendix
Appendix
Slide 11: Clinical trial overview: INDV-6001 and INDV-2000
Trial Population Patients Design Primary Endpoints Status Estimated Completion INDV-6001 3-month long- acting buprenorphine Phase II NCT06576843 Moderate to severe Opioid Use Disorder (OUD) 122 Multiple dose Phase II PK study Evaluate PK, safety and tolerability of INDV-6001 following multiple doses
Slide 12: Financial Reconciliations
1. We have not provided the forward-looking GAAP equivalents for certain forward-looking non-GAAP metrics, including Non-GAAP Operating Profit, Non-GAAP Gross Margin, Non-GAAP SG&A, and Non-GAAP Operating Expense, or GAAP reconciliations of any of the aforementioned, as a result of the uncertainty r
Slide 13: ae INDIVIOR
ae INDIVIOR